Sepsis and Septic Shock research hub

A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

This early-stage study is looking at a new medicine called M6229. We want to see how safe it is and how it acts in healthy people. This is to make sure it's safe to test in people with serious conditions like sepsis later on.